Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
This is a long-term follow up study evaluating the safety of BPX-501 T cells
 (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.
Subjects enrolled on the BP-004 study who have completed or discontinued from the study, and
 are beyond Day 180 will be requested to enroll on this long-term follow up protocol. Long
 term follow up for gene therapy clinical and safety endpoints will continue up to 15 years.
Inclusion Criteria:

 -  Signed written informed consent by the patient or the patient's guardian for children
 who are minors

 -  Enrolled on BP-004 protocol, received BPX-501 infusion, completed or discontinued from
 the study, and are beyond Day +180.

 Exclusion Criteria:

 -  Lack of parents'/guardian's informed consent for children who are minors

 -  Loss of allograft prior to 6 months